Witzig T - Search Results

1

Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.

Damlaj M, Sulai NH, Oliveira JL, Ketterling RP, Hashmi S, Witzig T, Nowakowski G, Call TG, Shanafelt TD, Ding W, Hogan WJ, Litzow MR, Patnaik MM. Damlaj M, et al. Among authors: witzig t. Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):699-704. doi: 10.1016/j.clml.2015.07.643. Epub 2015 Aug 5. Clin Lymphoma Myeloma Leuk. 2015. PMID: 26422251

2

Refractory and relapsing multiple myeloma treated by blood stem cell transplantation.

Gertz MA, Pineda AA, Chen MG, Letendre L, Greipp PR, Solberg LA Jr, Witzig TE, Garton JP, Inwards DJ, Litzow MR, et al. Gertz MA, et al. Among authors: witzig te. Am J Med Sci. 1995 Mar;309(3):152-61. doi: 10.1097/00000441-199503000-00006. Am J Med Sci. 1995. PMID: 7879820

3

Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.

Witzig TE, Weitz JJ, Lundberg JH, Tefferi A. Witzig TE, et al. Leuk Lymphoma. 1994 Jun;14(1-2):137-9. doi: 10.3109/10428199409049659. Leuk Lymphoma. 1994. PMID: 7920220

4

Effects of phenylacetate on cells from patients with B-chronic lymphocytic leukemia.

Call TG, Stenson MJ, Witzig TE. Call TG, et al. Among authors: witzig te. Leuk Lymphoma. 1994 Jun;14(1-2):145-9. doi: 10.3109/10428199409049661. Leuk Lymphoma. 1994. PMID: 7920222

5

Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: when is the optimal time for stem cell harvest?

Witzig TE, Gertz MA, Lust JA, Kyle RA, Greipp PR. Witzig TE, et al. Leuk Lymphoma. 1995 Nov;19(5-6):417-22. doi: 10.3109/10428199509112199. Leuk Lymphoma. 1995. PMID: 8590841

6

A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma.

Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA. Gertz MA, et al. Among authors: witzig te. Leukemia. 1995 Dec;9(12):2115-8. Leukemia. 1995. PMID: 8609725 Clinical Trial.

7

Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation.

Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR. Gertz MA, et al. Among authors: witzig te. Bone Marrow Transplant. 1997 Feb;19(4):337-42. doi: 10.1038/sj.bmt.1700670. Bone Marrow Transplant. 1997. PMID: 9051243

8

A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma.

Witzig TE, Camoriano JK, Schroeder G, Kurtin PJ, Habermann TM. Witzig TE, et al. Leuk Lymphoma. 1998 Jan;28(3-4):307-14. doi: 10.3109/10428199809092686. Leuk Lymphoma. 1998. PMID: 9517502 Clinical Trial.

9

Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia.

Witzig TE, Kimlinger T, Stenson M, Therneau T. Witzig TE, et al. Leuk Lymphoma. 1998 Sep;31(1-2):167-75. doi: 10.3109/10428199809057596. Leuk Lymphoma. 1998. PMID: 9720726

10

Alberts SR, Bretscher M, Wiltsie JC, O'Neill BP, Mokri B, Witzig TE. Alberts SR, et al. Among authors: witzig te. Leuk Lymphoma. 1999 Feb;32(5-6):489-96. doi: 10.3109/10428199909058406. Leuk Lymphoma. 1999. PMID: 10048421

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

645 results

Search Page

Filters